ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

DAWN Day One Biopharmaceuticals Inc

17.25
-0.32 (-1.82%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Day One Biopharmaceuticals Inc DAWN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.32 -1.82% 17.25 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.00 17.13 18.00 17.17 17.57
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/3/202415:19EDGAR2Form 8-K - Current report
28/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:27EDGAR2Form 144 - Report of proposed sale of securities
20/2/202417:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:51EDGAR2Form 144 - Report of proposed sale of securities
17/1/202407:25EDGAR2Form 8-K - Current report
09/1/202418:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202418:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202407:30EDGAR2Form 8-K - Current report
04/1/202415:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
17/11/202317:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202317:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202306:07EDGAR2Form 8-K - Current report
16/11/202317:24EDGAR2Form 144 - Report of proposed sale of securities
15/11/202315:07EDGAR2Form 8-K - Current report
06/11/202315:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:30EDGAR2Form 8-K - Current report
30/10/202309:54DJNDay One Biopharmaceuticals Shares Rally on FDA Priority..
30/10/202307:58DJNDay One Gets FDA Priority Review of Tovorafenib in Pediatric..
30/10/202307:12EDGAR2Form 8-K - Current report
20/10/202315:01EDGAR2Form SC 13D/A - General statement of acquisition of..
14/9/202316:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
11/9/202307:35EDGAR2Form 8-K - Current report
17/8/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202317:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202307:06EDGAR2Form 8-K - Current report
07/8/202315:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:30EDGAR2Form 8-K - Current report
05/7/202318:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/6/202306:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..

Su Consulta Reciente

Delayed Upgrade Clock